IMMUNEXT
ImmuNext develops compounds on the cutting edge of immunotherapy for cancer and autoimmune diseases. Novel immunomodulators have been partnered with Janssen, Roche and Sanofi. ImmuNext currently has a clinical stage program with VISTA, a checkpoint regulator, and pre-clinical programs focused on the development of antibodies that target novel immuno-metabolic proteins.
IMMUNEXT
Industry:
Biotechnology
Address:
Lebanon, New Hampshire, United States
Country:
United States
Website Url:
http://www.immunext.com
Status:
Active
Email Addresses:
[email protected]
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF Google Font API WordPress Font Awesome Apache Wordpress Plugins Mobile Non Scaleable Content Google Apps For Business
Current Employees Featured
Official Site Inspections
http://www.immunext.com Semrush global rank: 4.83 M Semrush visits lastest month: 1.87 K
- Host name: a2aa9ff50de748dbe.awsglobalaccelerator.com
- IP address: 3.33.130.190
- Location: Seattle United States
- Latitude: 47.6348
- Longitude: -122.3451
- Metro Code: 819
- Timezone: America/Los_Angeles
- Postal: 98109
More informations about "ImmuNext"
ImmuNext - Crunchbase Company Profile & Funding
ImmuNext develops compounds on the cutting edge of immunotherapy for cancer and autoimmune diseases. Novel immunomodulators have been partnered …See details»
ImmuNext, Inc. - Drug pipelines, Patents, Clinical trials - Synapse
Mar 8, 2025 The ImmuNext transaction gave Royalty access to royalties and milestone payments on a drug now under development by Sanofi. ... The statistics for drugs in the …See details»
Small Company Makes Big Strides in Treating …
Jan 31, 2020 In 2013 ImmuNext received both a Phase I STTR and a Phase II SBIR to investigate another target of immune malfunction which could potentially treat disorders like multiple sclerosis (MS) and lupus. Funding from a fast …See details»
ImmuNext Inc - Company Profile and News - Bloomberg Markets
Company profile page for ImmuNext Inc including stock price, company news, executives, board members, and contact informationSee details»
Lilly and ImmuNext Announce Licensing and Research …
INDIANAPOLIS and LEBANON, N.H., March 26, 2019 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and ImmuNext, Inc. today announced a global licensing and research …See details»
Sanofi and ImmuNext Enter into Agreement to Develop …
Jan 9, 2017 BRIDGEWATER, N.J. and LEBANON, N.H., Jan. 9, 2017 /PRNewswire/ -- Sanofi and ImmuNext, Inc., announced today an agreement focused on the development of a novel …See details»
ImmuNext (Royalty Interest in Frexalimab) - PitchBook
ImmuNext (Royalty Interest in Frexalimab) General Information Description. Royalty interest of Frexalimab in Lebanon, New Hampshire. It is a first-in-class, second-generation anti-CD40 …See details»
Small Company Makes Big Strides in Treating Autoimmune …
ImmuNext researchers focused on developing a second drug by re-engineering the first. “We were able to modify the original [cancer] drug to do the opposite, which is to slow down the …See details»
IMMUNEXT PHARMACEUTICALS | SBIR.gov
ImmuNext has defined an anti-MCT1 monoclonal antibody (mAb) that will be developed for the treatment of human autoimmune disease. The membrane monocarboxylate nutrient …See details»
ImmuNext, Inc. (ImmuNext, Inc.) - 药物管线_专利_临床试验_投融营 …
了解ImmuNext, Inc. (ImmuNext, Inc.)公司的药物管线，治疗领域，技术平台，以及它的56篇新闻和5篇文献，疾病领域:神经系统疾病，免疫系统疾病，内分泌与代谢疾病，技术平台:单克隆抗 …See details»
Patents Assigned to IMMUNEXT INC. - Justia Patents Search
Apr 17, 2017 Assignees: ImmuNext, Inc., JANSSEN PHARMACEUTICAL NV Inventors: Catherine Carriere, Michael Molloy, Jay Rothstein, Linda Snyder, Gordon Powers Anti-human …See details»
Frexalimab in Relapsing Multiple Sclerosis and Non-Relapsing …
Acknowledgements: Sanofi is developing frexalimab (SAR441344) under an exclusive license from ImmuNext Inc. The authors and Sanofi would like to thank the trial investigators, …See details»
Lilly, ImmuNext Launch Up-to-$605M+ Autoimmune Disease …
Mar 27, 2019 Eli Lilly will partner with ImmuNext to study and develop a preclinical novel potential target for autoimmune disease treatments, the companies said, through an up-to …See details»
SBIR-STTR-Success: Small Company Makes Big Strides in Treating ...
Jun 23, 2022 In 2013 ImmuNext received both a Phase I STTR and a Phase II SBIR to investigate another target of immune malfunction which could potentially treat disorders like …See details»
Identification Of Vsig8 As The Putative Vista Receptor (v-r) And …
The applicant listed for this patent is IMMUNEXT, INC.. Invention is credited to Yalin Guo, Michael Molloy, Michael Rosenzweig, Jay Rothstein. ... (T3) and a C-terminal globular domain (TC). …See details»
Frexalimab Reduces Plasma Neurofilament Light Chain in …
EAN 2024 ePresentation EPR-230 • This Phase 2 trial (NCT04879628) is funded by Sanofi. • Sanofi is developing frexalimab (SAR441344) under an exclusive license from ImmuNext Inc. • …See details»
Royalty Pharma To Acquire Royalty Interest In ImmuNext’s …
May 9, 2024 The Life Sciences and M&A teams advised ImmuNext, Inc. in its agreement with Royalty Pharma plc (Nasdaq: RPRX) in which Royalty Pharma will acquire royalties and …See details»
Frexalimab royalty acquisition
1. Royalty Pharma will receive 100% of net royalties on annual worldwide net sales of frexalimabof up to $2.0 billion and share a minority of the royalties above this threshold with …See details»
Frexalimab - ImmuNext/Sanofi - AdisInsight - Springer
Dec 19, 2024 Frexalimab - ImmuNext/Sanofi Alternative Names: INX 021; SAR-441344 Latest Information Update: 19 Dec 2024 Price : $50 * Buy Profile. Note: Adis is an information …See details»
This immune checkpoint could be a new target against cancer, …
Jan 16, 2020 ImmuNext had originally teamed up with Johnson & Johnson on anti-VISTA antibody JNJ-61610588, but the Big Pharma returned the rights for what it called “business …See details»